New eye injection shows promise for rare eye cancer
Disease control
Recruiting now
This study tests an eye injection of ADX-2191 (a form of methotrexate) in 20 adults with primary vitreoretinal lymphoma, a rare eye cancer. The goal is to see if it safely clears cancer cells from the eye. Participants receive injections at different frequencies over eight weeks.
Phase: PHASE3 • Sponsor: Aldeyra Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 10:28 UTC